Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Directors' Dealings

In accordance with Section 15a German Securities Trading Act (WpHG) the members of the Executive Board and the Supervisory Board of Merck KGaA as well as persons with regular access to inside information and who are authorized to make important managerial decisions are obliged immediately to notify Merck KGaA, Darmstadt, Germany, and the Federal Financial Supervisory Authority (BaFin) of own transactions in shares of Merck KGaA, Darmstadt, Germany, or financial instruments based on them. This obligation applies also to other parties who are closely associated with such persons such as spouses, registered civil partners and dependent children. Merck KGaA, Darmstadt, Germany, is obliged to immediately publish the information. A respective provision is also contained in Section 6.6. German Corporate Governance Codex.


Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
Open the following links in a RSS Reader of your choice